Drug-set enrichment analysis: a novel tool to investigate drug mode of action.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26415724.
- Also identified by DOI 10.1093/bioinformatics/btv536 and PMC identifier 4795590.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Automated screening approaches are able to rapidly identify a set of small molecules inducing a desired phenotype from large small-molecule libraries. However, the resulting set of candidate molecules is usually very diverse pharmacologically, thus little insight on the shared mechanism of action (MoA) underlying their efficacy can be gained. We introduce a computational method (Drug-Set Enrichment Analysis-DSEA) based on drug-induced gene expression profiles, which is able to identify the molecular pathways that are targeted by most of the drugs in the set. By diluting drug-specific effects unrelated to the phenotype of interest, DSEA is able to highlight phenotype-specific pathways, thus helping to formulate hypotheses on the MoA shared by the drugs in the set. We validated the method by analysing five different drug-sets related to well-known pharmacological classes. We then applied DSEA to identify the MoA shared by drugs known to be partially effective in rescuing mutant cystic fibrosis transmembrane conductance regulator (CFTR) gene function in Cystic Fibrosis. The method is implemented as an online web tool publicly available at http://dsea.tigem.it. dibernardo@tigem.it Supplementary data are available at Bioinformatics online.
Medical subject headings
- Cystic Fibrosis
- Cystic Fibrosis Transmembrane Conductance Regulator
- Gene Expression Regulation
- Mutation
- Small Molecule Libraries
- Transcriptome